Patients with noninfectious intermediate, posterior or panuveitis treated with adalimumab experienced improved best corrected visual acuity and reduced daily uveitis-related systemic corticosteroid use.
Patients with uveitis were enrolled in VISUAL III, a phase 3, open-label, multicenter clinical trial extension. Patients received Humira (adalimumab, AbbVie) 40 mg every other week, and follow-up was through 78 weeks.
In total, 371 of 424 patients were included in the intent-to-treat analysis. The beginning of the study included 242 patients with active uveitis, and 145 of those patients
Uncategorized